Osaic Holdings
ALLO icon

Osaic Holdings’s Allogene Therapeutics ALLO Stock Holding History

Osaic Holdings’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.5K Buy
45,442
+5,002
+12% +$11K ﹤0.01% 4996
2026
Q1 		$98.7K Sell
40,440
-26
-0.1% -$52 ﹤0.01% 4705
2025
Q4 		$55.4K Hold
40,466
– – ﹤0.01% 5158
2025
Q3 		$45.8K Hold
40,466
– – ﹤0.01% 5369
2025
Q2 		$45.7K Buy
40,466
+7,466
+23% +$9.92K ﹤0.01% 5116
2025
Q1 		$48.2K Buy
33,000
+12,310
+59% +$23.2K ﹤0.01% 4748
2024
Q4 		$44.1K Buy
20,690
+2,240
+12% +$5.53K ﹤0.01% 4803
2024
Q3 		$51.7K Sell
18,450
-301
-2% -$802 ﹤0.01% 4722
2024
Q2 		$43.7K Buy
18,751
+8,357
+80% +$24.7K ﹤0.01% 4787
2024
Q1 		$46.5K Sell
10,394
-1,605
-13% -$6.7K ﹤0.01% 4805
2023
Q4 		$38.5K Sell
11,999
-201
-2% -$570 ﹤0.01% 5069
2023
Q3 		$38.7K Buy
12,200
+8,780
+257% +$38.5K ﹤0.01% 5169
2023
Q2 		$17K Sell
3,420
-4,745
-58% -$25.7K ﹤0.01% 5678
2023
Q1 		$40.3K Sell
8,165
-4,423
-35% -$28.4K ﹤0.01% 5096
2022
Q4 		$79K Sell
12,588
-5,521
-30% -$51.1K ﹤0.01% 4621
2022
Q3 		$196K Sell
18,109
-9,529
-34% -$129K ﹤0.01% 3765
2022
Q2 		$315K Buy
27,638
+16,270
+143% +$144K ﹤0.01% 3378
2022
Q1 		$103K Buy
11,368
+640
+6% +$6.67K ﹤0.01% 4576
2021
Q4 		$160K Buy
10,728
+359
+3% +$6.33K ﹤0.01% 4155
2021
Q3 		$266K Buy
10,369
+2,231
+27% +$53K ﹤0.01% 3643
2021
Q2 		$212K Buy
8,138
+2,107
+35% +$60.1K ﹤0.01% 3818
2021
Q1 		$214K Buy
6,031
+1,862
+45% +$62.8K ﹤0.01% 3669
2020
Q4 		$105K Buy
4,169
+2,369
+132% +$77.2K ﹤0.01% 3999
2020
Q3 		$68K Buy
1,800
+124
+7% +$4.67K ﹤0.01% 4087
2020
Q2 		$72K Sell
1,676
-1
-0.1% -$36 ﹤0.01% 3921
2020
Q1 		$33K Buy
+1,677
New +$39.9K ﹤0.01% 4290

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Osaic Holdings's ALLO Position: Q2 2026 in Review

Osaic Holdings increased its Allogene Therapeutics (ALLO) stake by 12% in Q2 2026, buying an estimated $11K and bringing the position to 45,442 shares worth $94.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4996.

Osaic Holdings first reported a position in ALLO in Q1 2020 and has held it in 26 quarters since. The position peaked at $315K in Q2 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Osaic Holdings held 45,442 shares of Allogene Therapeutics worth $94.5K as of Q2 2026.
  • Osaic Holdings bought 5,002 Allogene Therapeutics shares in Q2 2026, an estimated $11K.
  • Allogene Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4996 holding.
  • Osaic Holdings first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Allogene Therapeutics position peaked at $315K in Q2 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.